Viron Therapeutics, Inc.

Western Michigan University

Karim Essani

Grant McFadden

David Jeng

Steven J Conrad

A composition for treating cancerous cells in a subject having an immune system includes a virus in thegenus having at least one mutation. In one embodiment, the mutation results in suppressed expression of a TNF binding protein by the virus. In another embodiment, the mutation results in suppressed expression of thymidine kinase ('TK') by the virus. In another embodiment, the mutation arms the virus with a transgene to express a bacterial flagellin. The mutations can be present singly or in combination. Additional aspects include a method of treating cancerous cells with a composition as described herein, and a method of delivering at least one gene to cancerous cells in a subject.

Composition for treating cancerous cells and a method therefor

The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.

Growing community of inventors

Kalamazoo, MI, United States of America

Karim Essani